B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC6A3

MOLECULAR TARGET

solute carrier family 6 member 3

UniProt: Q01959NCBI Gene: 653170 compounds

SLC6A3 (solute carrier family 6 member 3) is targeted by 70 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC6A3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Duloxetine Hydrochloride3.0019
2Fluoxetine2.9418
3Modafinil2.9418
4Sertraline2.208
5Venlafaxine Hydrochloride2.208
6Digoxin1.393
7Ouabain1.393
8Ticagrelor1.393
9Amlodipine1.102
10Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent1.102
11Aripiprazole1.102
12Benzethonium Bactericidal cationic quaternary ammonium surfactant used as1.102
13Cabergoline1.102
14Ethinyl Estradiol1.102
15Ibogaine1.102
16streptonigrin1.102
17Escitalopram S-enantiomer of CITALOPRAM. Belongs to0.691
18Luteolin 5,7,3',4'-tetrahydroxy-flavone,0.691
19Simvastatin0.691
20Amoxapine0.691
21Antazoline0.691
22Astemizole Antihistamine drug now withdrawn from0.691
23Axitinib0.691
24Benzydamine0.691
25Calcitriol0.691
26Canagliflozin0.691
27Carvedilol0.691
28Caspofungin0.691
29Celecoxib0.691
30Cetirizine0.691
31Chlorhexidine0.691
32Chlorpheniramine0.691
33cinacalcet0.691
34Cinnarizine0.691
35Crizotinib0.691
36Cyclizine0.691
37Dequalinium0.691
38Digitoxin0.691
39Domperidone0.691
40Estrone0.691
41Flunarizine Flunarizine is0.691
42Fluspirilene0.691
43Fluvoxamine0.691
44Hexachlorophene0.691
45Indomethacin0.691
46Labetalol0.691
47Leflunomide0.691
48lidoflazine0.691
49Loratadine0.691
50Maprotiline0.691

Showing top 50 of 70 compounds. Use the BiohacksAI search to explore all SLC6A3 modulators.

About SLC6A3 as a Drug Target

SLC6A3 (solute carrier family 6 member 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 70 compounds with documented SLC6A3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC6A3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.